ABLIM1 and cancer: By querying the CBioPortal database for cancer genomics, we found that augmented expression ABLIM1 significantly predicted short disease-free survival time in CRC patients in two independent studies (TCGA PanCancer Atlas, P = 0.034, hazard ratio = 2.34; TCGA Firehose Legacy, P = 0.024, hazard ratio = 1.65) (Fig. 1G, H), though no statistical significance was observed in overall survival analysis (Fig. S1B, C), which indicates ABLIM1 upregulation as an independent predictor of disease relapse.